ProCE Banner Activity

How I Use Checkpoint Inhibitors in Later-line Advanced Gastric/GEJ Cancers

Clinical Thought
Which of our patients with advanced gastric/GEJ cancers are most likely to benefit from later-line treatment with PD-1 inhibitors? Here’s my take on applying the latest evidence to the clinic.

Released: July 18, 2019

Expiration: July 16, 2020

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD, FACP

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I
Chair and Consultant, Division of Hematology and Medical Oncology
Professor
Mayo Clinic College of Medicine and Science
Mayo Clinic in Arizona
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Armo, AstraZeneca, Imugene, Immuneering, and Pieris.